CANADA - 2025/06/14: In this photo illustration, the Viking Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesViking Therapeutics (NASDAQ: VKTX) fell 42% on August 19, 2025, after Phase 2 results for its oral obesity pill VK2735 disappointed investors. The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli Lilly ...